Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
about
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisTreating multiple sclerosis with monoclonal antibodies: a 2013 update.CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MSCytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine stormBiological agents for the treatment of uveitis.Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.Human CD56bright NK Cells: An Update.Use of Disease-Modifying Therapies in Pediatric MS.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.Daclizumab.Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.Role of Natural Killer Cells in Multiple SclerosisUnusual expansion of CD3+CD56+ natural killer T-like cells in peripheral blood after anticytokine treatment for graft-versus-host disease: A case report
P2860
Q28066677-4A7B035C-9B02-489C-8837-F4C8029E9938Q34330211-10DDAD86-B620-47F7-980D-0128D6F9761BQ35023350-8BC30EB0-8EE5-492D-B25A-63744E39D998Q36621100-27B5386D-B7D3-4F08-80E7-D65C65F2057FQ37984565-5AC0628B-36ED-405E-8690-F8BAF68FA954Q38111620-CAA83170-5B3B-4C77-B505-230EB0DA0062Q38172961-DD83E388-A547-484E-AFEA-9999B5A2757AQ38286209-96A5A288-84E9-4B52-8962-37C49CA764E1Q38729214-544C0C4E-0E84-4A6F-91DF-F8633BC93E3AQ38747100-E0747332-D2E0-450B-807A-50AA4BB03CE0Q38781384-45D9F958-D6E9-446C-BD39-C8E6D0A4F9FBQ38868197-5191FF8F-4C03-4150-B2FD-936824BF46EAQ38960854-395B078B-B969-4847-9ED9-A906A8BCAFE9Q42103395-F4BB09EE-7394-46AD-96F2-B37F40BF3FB2Q43905322-13962C30-3E14-46E8-9BDA-4803F871C37EQ46487963-6B43CAA9-2508-46E7-BA0B-1520B116F21FQ50871333-FCF08470-1930-4780-BF9C-9F5C885F45D6Q58692418-993B36F6-66CB-4933-823B-F08C167B6BECQ58704073-5FED985A-FD87-443D-B7E0-20341EFC6D56
P2860
Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Intermediate-affinity interleukin-2 receptor expression predicts CD56
@nl
Intermediate-affinity interleu ...... ients with multiple sclerosis.
@en
type
label
Intermediate-affinity interleukin-2 receptor expression predicts CD56
@nl
Intermediate-affinity interleu ...... ients with multiple sclerosis.
@en
prefLabel
Intermediate-affinity interleukin-2 receptor expression predicts CD56
@nl
Intermediate-affinity interleu ...... ients with multiple sclerosis.
@en
P2093
P2860
P356
P1476
Intermediate-affinity interleu ...... ients with multiple sclerosis.
@en
P2093
Jacob S Elkins
James P Sheridan
Jeffrey Harris
Katherine Riester
Lyubov Efros
Meina T Tang
Vladimir Vexler
Ying Zhang
P2860
P304
P356
10.1177/1352458511414755
P577
2011-08-01T00:00:00Z